Warning Letter Record: Specialty Health Products CO, LLC (2026-07-07) — CGMP/QSR/Medical Devices/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/QSR/Medical Devices/Adulterated
TL;DR
Key takeaway: On July 7, 2026, the FDA's Center for Devices and Radiological Health issued Warning Letter CMS #726564 to Specialty Health Products CO, LLC (Phoenix, AZ) regarding adulteration of the Hydro-San Plus, Aqua Cleanse Colonic Irrigation Systems, and Speculum Kits under 21 U.S.C. § 351(h) due to violations of Current Good Manufacturing Practice (CGMP) requirements at 21 CFR Part 820. Specific deficiencies include: failure to establish design validation procedures for biocompatibility testing per ISO 10993 standards and shelf-life validation (despite claimed 7-year shelf life); inadequate risk analysis; non-compliant disinfection instructions; and failure to document design changes via Engineering Change Orders as required by 21 CFR 820.30(i). The FDA found the firm's responses dated January 5 through June 10, 2026 inadequate to address these violations.
Argus analysis
# FDA Warning Letter Analysis: Specialty Health Products CO, LLC
**Company and Findings**
Specialty Health Products CO, LLC, based in Phoenix, Arizona, manufactures colonic irrigation systems including the Hydro-San Plus, Aqua Cleanse, and associated speculum kits. During an FDA inspection from December 1–11, 2025, investigators determined these products are Class II medical devices. The FDA issued a warning letter on July 7, 2026, citing multiple violations of Current Good Manufacturing Practice (CGMP) requirements. The Center for Devices and Radiological Health (CDRH) identified the products as adulterated under section 501(h) of the Federal Food, Drug, and Cosmetic Act because manufacturing controls did not meet Quality System Regulation standards.
**Regulatory Citations**
The warning letter cites five major CGMP violations under 21 CFR Part 820. These include: design validation procedures (§820.30(g)), design change control (§820.30(i)), production process controls (§820.70(a)), and complaint handling procedures (§820.198(a)). Collectively, these regulations require manufacturers to validate device designs meet user needs, document all design modifications formally, establish documented production processes with defined acceptance criteria, and maintain systematic complaint investigation procedures. The violations are significant because they address foundational quality system elements: design controls ensure devices function safely as intended, process controls verify manufactured units meet specifications, and complaint systems identify potential safety issues requiring investigation or regulatory reporting.
**Response Timeline and Industry Monitoring**
The firm submitted six responses between January and June 2026, which the FDA deemed inadequate. The warning letter indicates the firm has not conducted required biocompatibility testing per ISO 10993 standards, lacks shelf-life validation data despite claiming seven-year shelf life, has undocumented design changes, and has not properly investigated customer complaints. Compliance officers monitoring this firm should expect follow-up enforcement action if corrections remain insufficient. Industry peers should note the emphasis on documentation: missing test records, undocumented design changes, and incomplete complaint investigations were recurring deficiencies throughout multiple CAPA responses.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Specialty Health Products CO, LLC MARCS-CMS 726564 — July 07, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name John C. Kavanagh Recipient Title QA/RA Manager Specialty Health Products CO, LLC 2514 E Mohawk Ln, Suite 111 Phoenix , AZ 85050 United States (b)(6), (b)(7)(C) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS # 726564 July 7, 2026 Dear Mr. Kavanagh: During an inspection of your firm located in Phoenix, AZ, from December 1, 2025, through December 11, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit), the Aqua Cleanse Colonic Irrigation System, and Speculum Kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Quality System Regulation Violation(s) Our inspection revealed that the Hydro-San Plus, Aqua Cleanse, and Speculum Kits are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) Regulation found at 21 CFR Part 820. We received your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026. These responses are not adequate for the reasons described below. 1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). Specifically, your firm has not conducted design validation for your biocompatibility or shelf life requirements of the Class II colonic irrigation devices (Hydro-San Plus and Aqua Cleanse). a. Your firm does not have evidence that biocompatibility testing per ISO 10993 standards was conducted for the (b)(4) material used in patient-contacting speculums despite your specifications requiring compliance to ISO 10993: Biological Evaluation of Medical Devices. Your QA/RA Manager stated that no such records exist. b. Your firm does not have shelf-life validation studies or accelerated aging data to support the claimed 7-year shelf life for the Hydro-San Plus, despite your own risk analysis document explicitly acknowledging a 7-year shelf life due to possible deterioration of components. c. Your firm…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Specialty Health Products CO, LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Specialty Health Products CO, LLC as of 2026-09-22. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Specialty Health Products CO, LLC (2026-07-07) — CGMP/QSR/Medical Devices/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-specialty-health-products-co-llc-2026-07-07-cgmp
"Warning Letter Record: Specialty Health Products CO, LLC (2026-07-07) — CGMP/QSR/Medical Devices/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-specialty-health-products-co-llc-2026-07-07-cgmp.
Argus HQ Research. "Warning Letter Record: Specialty Health Products CO, LLC (2026-07-07) — CGMP/QSR/Medical Devices/Adulterated." Digital Empire Holdings LLC. Accessed September 27, 2026. https://argushq.ai/fda/warning-letter/fda-wl-specialty-health-products-co-llc-2026-07-07-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_specialty_health_products_co_llc_2026_07_07_cgmp_2026,
title = {Warning Letter Record: Specialty Health Products CO, LLC (2026-07-07) — CGMP/QSR/Medical Devices/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-specialty-health-products-co-llc-2026-07-07-cgmp},
note = {Accessed: September 27, 2026}
}